Fast Five Quiz: Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Karl J. D'Silva, MD


June 23, 2020

Patients who have undergone previous treatments are more likely to develop the del(17p)/TP53 mutation, suggesting that CLL clones with del(17p) change during treatment. Clinical trials are recommended for the treatment of patients with this mutation. Alternatively, for individuals without substantial comorbidities who are refractory to small-molecule inhibitor therapy, allogeneic hematopoietic stem cell transplantation may be considered.

Learn more about recent advances in CLL.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: